β¨ Medicine Distribution Notices
20 JULY 2006
NEW ZEALAND GAZETTE, No. 82
2587
Product:
Octaplas (Blood Group O)
Active Ingredient:
Plasma protein fraction 9-14g
Dosage Form:
Solution for injection
New Zealand Sponsor:
Octapharma New Zealand Limited
Manufacturer:
Octapharma Pharmazeutika Produktionsges, Vienna, Austria
Product:
Prexige
Active Ingredient:
Lumiracoxib 100mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland
Product:
Redoxon Double Action
Active Ingredients:
Ascorbic acid 1,000mg
Zinc citrate 32mg equivalent to zinc 10mg
Dosage Form:
Effervescent tablet
New Zealand Sponsor:
Bayer (NZ) Limited
Manufacturer:
Roche Products Pty Limited, Dee Why, New South Wales, Australia
Product:
Riamet
Active Ingredients:
Artemether 20mg
Lumefantrine 120mg
Dosage Form:
Tablet
New Zealand Sponsor:
Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer:
Novartis Pharma Beijing, Nanguan, Chengguan Township, Changping County, Beijing, China
Dated this 13th day of July 2006.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go4894
Consent to the Distribution of a Changed Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set out in the Schedule hereto:
Schedule
Product:
Glivec
Active Ingredient:
Imatinib mesilate 119.5mg equivalent to 100mg imatinib base
Dosage Form:
Capsule
New Zealand Sponsor:
Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland
Product:
Glivec
Active Ingredient:
Imatinib mesilate 59.75mg equivalent to 50mg imatinib base
Dosage Form:
Capsule
New Zealand Sponsor:
Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland
Product:
Glivec
Active Ingredient:
Imatinib mesilate 119.5mg equivalent to 100mg imatinib base
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland
Product:
Glivec
Active Ingredient:
Imatinib mesilate 478mg equivalent to 400mg imatinib base
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland
Dated this 13th day of July 2006.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go4893
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2006, No 82
Gazette.govt.nz —
NZ Gazette 2006, No 82
β¨ LLM interpretation of page content
π₯
Consent to the Distribution of New Medicines
(continued from previous page)
π₯ Health & Social Welfare13 July 2006
Medicines, Distribution, Octaplas, Prexige, Redoxon Double Action, Riamet
- DON MATHESON, Deputy Director-General, Public Health
π₯ Consent to the Distribution of a Changed Medicine
π₯ Health & Social Welfare13 July 2006
Medicines, Distribution, Glivec
- DON MATHESON, Deputy Director-General, Public Health
π₯ Renewal of Provisional Consent to the Distribution of a New Medicine
π₯ Health & Social WelfareMedicines, Provisional Consent, Renewal